ArticleRSC advances2025
β-caryolane derivatives as novel anti-colorectal cancer agents: synthesis and
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Caryolane derivatives possess a unique skeletal structure and a wide range of practical applications. Recent studies suggest that certain β-caryolane derivatives may exhibit enhanced anti-colorectal cancer activity compared to their natural parent compounds, β-caryolanol and β-caryophyllene (β-CP). However, the structural diversity of known β-caryolane derivatives remains limited, likely due to challenges in their synthesis. In this study, we systematically investigated, for the first time, the reactivity of three nucleophiles (sulfonamides, amides, and azide) with β-CP under acid catalysis. The corresponding β-caryolane-type products were successfully obtained in a single step. The azide-addition product further underwent click reactions with various alkynes to yield triazole derivatives. Compared to β-CP or β-caryolanol, most amino-substituted β-caryolane derivatives demonstrated significantly improved anti-proliferative activity against several colorectal cancer cell lines, especially HT-29 cells. Among them, compound NC-19 showed the most potent antiproliferative effect against HT-29 cells with an IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.